Jaundice, also known as hyperbilirubinemia, is a yellow discoloration of the body tissue resulting from the accumulation of an excess of bilirubin. Deposition of bilirubin happens only when there is an excess of bilirubin, a sign of increased production or impaired excretion. The normal serum levels of bilirubin are less than 1mg/dl; however, the clinical presentation of jaundice as scleral icterus (peripheral yellowing of the eye sclera), is best appreciated only when the levels reach more than 3 mg/dl. Sclerae have a high affinity for bilirubin due to their high elastin content. With further increase in serum bilirubin levels, the skin will progressively discolor ranging from lemon yellow to apple green, especially if the process is long-standing; the green color is due to biliverdin.
Bilirubin has two components: unconjugated(indirect) and conjugated(direct), and hence elevation of any of these can result in jaundice. Icterus acts as an essential clinical indicator for liver disease, apart from various other insults.
Yellowing of skin sparing the sclerae is indicative of carotenoderma which occurs in healthy individuals who consume excessive carotene-rich foods.
Defect of canalicular organic anion transport 
Defect of sinusoidal reuptake of conjugated bilirubin
Decreased intrahepatic excretion of bilirubin
Extrahepatic cholestasis (biliary obstruction)
Excess production of bilirubin
Reduced hepatic uptake of bilirubin
The prevalence of jaundice differs among patient populations; newborns and elderly more commonly present with the disease.
The causes of jaundice also vary with age, as mentioned above. Around 20 percent of term babies are found with jaundice in the first week of life, primarily due to immature hepatic conjugation process. Congenital disorders, overproduction from hemolysis, defective bilirubin uptake, and defects in conjugation are also responsible for jaundice in infancy or childhood. Hepatitis A was found to be the most afflicting cause of jaundice among children. Bile duct stones, drug-induced liver disease, and malignant biliary obstruction occur in the elderly population.
Men have an increased prevalence of alcoholic and non-alcoholic cirrhosis, chronic hepatitis B, malignancy of pancreas, or sclerosing cholangitis. In contrast, women demonstrate higher rates of gallbladder stones, primary biliary cirrhosis, and gallbladder cancer.
Kernicterus or Bilirubin-induced neurologic dysfunction (BIND), a complication of severe jaundice is a very rare cause of death in neonates with a death rate of 0.28 deaths per one million live births.
Heme-->Biliverdin-->Bilirubin (insoluble due to tight hydrogen bonding)
Dysfunction in prehepatic phase results in elevated serum levels of unconjugated bilirubin while insult in post hepatic phase marks elevated conjugated bilirubin. Hepatic phase impairment can elevate both unconjugated and conjugated bilirubin.
Increased urinary excretion of urobilinogen can be due to increased production of bilirubin, increased reabsorption of urobilinogen from the colon, or decreased hepatic clearance of urobilinogen.
There are four different patterns of intrahepatic cholestasis, namely:
The histopathological changes of excess bile appear to result from the detergent effect of retained bile acids.
As mentioned earlier, the serum level of bilirubin is a balance between production and hepatic excretion. After reaching the colon, the bacteria metabolize it into urobilinogen. A vast majority of urobilinogen is converted in stercobilin and excreted in feces. About 10 to 20% of urobilin gets reabsorbed by the action of beta-glucuronidase in the brush border of the gut and facilitates enterohepatic circulation and re-excreted by the liver; less than 3mg/dl escapes the hepatic uptakes and filters into the urine.
Owing to its lipid soluble nature, bilirubin may cross the blood-brain barrier and thus enter the brain. Its clearance from the brain is ensured by the presence of an enzyme on the inner mitochondrial membrane, which aids in the oxidation of bilirubin, thus protecting against its neurotoxic effects. The mechanism of toxicity is yet obscure, but bilirubin has a higher affinity to settle in glia and neurons.
However, in newborns, since the blood-brain barrier is yet to develop, pathological increase in serum levels of bilirubin can result in death in the neonatal period or survival with disastrous neurological sequalae called kernicterus. Also, newborns are at increased risk due to lack of colonic bacteria resulting in deconjugation and enterohepatic reabsorption by b-glucuronidase enzymes resulting in hyperbilirubinemia.
History- Patients usually present with varying symptoms apart from yellowish discoloration of skin along with pruritus, thus providing clues to narrow down the etiology or can also be asymptomatic. A thorough questioning regarding the use of drugs, alcohol or other toxic substances, risk factors for hepatitis (travel, unsafe sexual practices), HIV status, personal or family history of any inherited disorders or hemolytic disorders is vital. Other important points include the duration of jaundice; and the presence of any coexisting signs and symptoms, like a joint ache, rash, myalgia, changes in urine and stool. A history of arthralgias and myalgias before yellowing indicates hepatitis, either due to drugs or viral infections.
Further, fever, chills, severe right-upper-quadrant-abdominal pain as seen in cholangitis and anorexia, malaise as seen in hepatitis and significant weight loss suggesting malignancy obstructing the bile ducts provide additional information for diagnosis. Additionally, a patient with a history of ulcerative colitis may present with hyperbilirubinemia due to PSC.
Physical examination begins by evaluation of body habitus and nutritional status. Temporal and proximal muscle wasting suggests malignancy or cirrhosis. It is worth reviewing the well-known stigmata of chronic liver disease, which includes spider nevi, palmar erythema, gynecomastia, caput medusae, Dupuytren contractures, parotid gland enlargement, and testicular atrophy. Palpable lymph nodes can also direct the clinician towards malignancy (left supraclavicular & periumbilical). Increased volume status of the patient evidenced by jugular venous distension can be a sign of right-sided heart failure, suggesting hepatic congestion.
The abdominal examination should provide information on the presence of hepatosplenomegaly, or ascites. Jaundice with ascites indicates either cirrhosis or malignancy with peritoneal spread.
Right upper quadrant tenderness with palpable gallbladder (Courvoisier sign) suggests obstruction of the cystic duct due to malignancy.
Liver function tests - to check serum levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase, serum albumin, protein, and bilirubin
AST, ALT and ALP levels - if the liver transaminase levels increase but ALP levels are low, then the insult is hepatic in origin.
Serum Bilirubin - whether there is a rise in unconjugated or conjugated bilirubin
In addition to the liver panel, all jaundiced patients should have additional tests such as albumin and prothrombin time – which are indicative of chronic and acute liver function, respectively. The inability of prothrombin time to correct with parenteral administration of vitamin K suggests severe hepatocellular dysfunction.
The results of the bilirubin, enzymes, and liver function tests will direct the diagnosis towards a hepatocellular or cholestatic cause and offer some idea of the duration and severity of the disease.
Further evaluation can be conducted based on the initial assessment.
Hepatocellular workup: viral serologies, autoimmune antibodies, serum ceruloplasmin, ferritin.
Cholestatic workup: Additional tests include abdominal ultrasound, CT, magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), endoscopic ultrasound (EUS).
Treatment of choice for jaundice is the correction of the underlying hepatobiliary or hematological disease, when possible.
Pruritis associated with cholestasis can be managed based on the severity. For mild pruritis, warm baths or oatmeal baths can be relieving. Antihistamines can also help with pruritis. Patients with moderate to severe pruritis respond to bile acid sequestrants such as cholestyramine or colestipol. Other less effective therapies include rifampin, naltrexone, sertraline, or phenobarbital. If medical treatments fail, liver transplantation may be the only effective therapy for pruritis.
Jaundice is an indication for hepatic decompensation and may be an indication for liver transplant evaluation depending on the severity of the hepatic injury.
The differential for yellowish discoloration of the skin is narrow. Healthy individuals with high consumption of vegetables and fruits that contain carotene, such as carrots can present with carotenoderma which classically spares the sclerae.
Quinacrine leads to yellowish discoloration of the skin in up to one-third of patients treated with it.
Prognosis of jaundice depends on the etiology.
Etiologies of jaundice with excellent prognosis include jaundice from resorption of hematomas, physiologic jaundice of newborn, breastfeeding, breast milk jaundice, Gilbert syndrome, choledocholithiasis.
As a general rule, malignant biliary obstructions and cirrhosis with jaundice predict a poorer prognosis.
Indirect (insoluble) bilirubin is harmful to cells and cellular structures. Due to the physiologic mechanisms that protect against elevated bilirubin, the toxic effects are limited to neonates due to the poorly developed blood-brain barrier. High levels of bilirubin are neurotoxic and can lead to permanent neurologic injury (kernicterus) (Bilirubin-induced neurologic dysfunction).
Specific challenging patients may require specialty consultations for further workup and management. Gastroenterology specialists most frequently consult on undiagnosed cases of jaundice.
Most cases of jaundice can be effectively prevented by following a few simple recommendations which include:
The best initial step in the evaluation of jaundice is history and physical examination. The next step is to classify jaundice by etiology and type-Hepatocellular, cholestatic or mixed.
The basic mechanisms of jaundice include elevated production, decreased uptake, and faulty conjugation.
Treatment focuses on the cause.
The biggest challenges in improving patient health outcome include a healthcare delivery system that focuses more on treating as opposed to preventing disease. Most cases of jaundice are preventable by vaccinations, safe sex practices, health education, risk factor modification.
The responsibility of the healthcare team in the incidence and management of jaundice is well known. Physicians, nurses, and pharmacists working together can significantly improve team outcomes. Encouragement from health care professionals to promote breastfeeding is vital in the management of neonatal jaundice.
With the wide range of etiologies for jaundice, the entire interprofessional team must collaborate to ensure optimal patient outcomes. Clinicians, including NPs and PAs, will be involved in the diagnosis and selection of therapy based on etiology. Nursing will work on patient compliance, and depending on the etiology, counseling the patient on lifestyle and other changes, and inform the treating clinicians about potential risks, non-compliance, and adverse reactions to therapy. Pharmacists are responsible for reporting back to the rest of the team on medication interactions following a medication review, and verifying dosing and duration; any concerns need to be brought to the attention of nursing and/or the prescriber. Only through this type of interprofessional collaboration can the healthcare team ensure the treatment matches the diagnosis and is executed in the best possible manner to bring about successful outcomes. [Level 5]
|||Schwarzenbach HR, [Jaundice and pathological liver values]. Praxis. 2013 Jun 5; [PubMed PMID: 23735764]|
|||Leung TS,Outlaw F,MacDonald LW,Meek J, Jaundice Eye Color Index (JECI): quantifying the yellowness of the sclera in jaundiced neonates with digital photography. Biomedical optics express. 2019 Mar 1; [PubMed PMID: 30891343]|
|||Roche SP,Kobos R, Jaundice in the adult patient. American family physician. 2004 Jan 15; [PubMed PMID: 14765767]|
|||Vítek L,Ostrow JD, Bilirubin chemistry and metabolism; harmful and protective aspects. Current pharmaceutical design. 2009; [PubMed PMID: 19754364]|
|||Al Nasser Y,Albugeaey M, Carotenemia 2019 Jan; [PubMed PMID: 30521299]|
|||Modha K, Clinical Approach to Patients With Obstructive Jaundice. Techniques in vascular and interventional radiology. 2015 Dec; [PubMed PMID: 26615159]|
|||Strassburg CP, Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best practice [PubMed PMID: 20955959]|
|||Nguyen KD,Sundaram V,Ayoub WS, Atypical causes of cholestasis. World journal of gastroenterology. 2014 Jul 28; [PubMed PMID: 25071336]|
|||Hucl T, [Malignant biliary obstruction]. Casopis lekaru ceskych. 2016; [PubMed PMID: 26898789]|
|||Fretzayas A,Moustaki M,Liapi O,Karpathios T, Gilbert syndrome. European journal of pediatrics. 2012 Jan; [PubMed PMID: 22160004]|
|||Memon N,Weinberger BI,Hegyi T,Aleksunes LM, Inherited disorders of bilirubin clearance. Pediatric research. 2016 Mar; [PubMed PMID: 26595536]|
|||Muchowski KE, Evaluation and treatment of neonatal hyperbilirubinemia. American family physician. 2014 Jun 1; [PubMed PMID: 25077393]|
|||Maisels MJ,Gifford K,Antle CE,Leib GR, Jaundice in the healthy newborn infant: a new approach to an old problem. Pediatrics. 1988 Apr; [PubMed PMID: 3353184]|
|||Aggarwal R,Goel A, Hepatitis A: epidemiology in resource-poor countries. Current opinion in infectious diseases. 2015 Oct; [PubMed PMID: 26203853]|
|||Linder KA,Malani PN, Hepatitis A. JAMA. 2017 Dec 19; [PubMed PMID: 29094153]|
|||Ilic M,Ilic I, Epidemiology of pancreatic cancer. World journal of gastroenterology. 2016 Nov 28; [PubMed PMID: 27956793]|
|||Purohit T,Cappell MS, Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World journal of hepatology. 2015 May 8; [PubMed PMID: 25954476]|
|||Bousema S,Govaert P,Dudink J,Steegers EA,Reiss IK,de Jonge RC, [Kernicterus is preventable but still occurs]. Nederlands tijdschrift voor geneeskunde. 2015; [PubMed PMID: 25944067]|
|||HSIA DY, BILIRUBIN METABOLISM. Pediatric clinics of North America. 1965 Aug; [PubMed PMID: 14312834]|
|||Feuer G,Di Fonzo CJ, Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug metabolism and drug interactions. 1992; [PubMed PMID: 1511611]|
|||Le Pichon JB,Riordan SM,Watchko J,Shapiro SM, The Neurological Sequelae of Neonatal Hyperbilirubinemia: Definitions, Diagnosis and Treatment of the Kernicterus Spectrum Disorders (KSDs). Current pediatric reviews. 2017; [PubMed PMID: 28814249]|
|||Trépo C,Chan HL,Lok A, Hepatitis B virus infection. Lancet (London, England). 2014 Dec 6; [PubMed PMID: 24954675]|
|||Nishikawa H,Osaki Y, Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. Mediators of inflammation. 2015; [PubMed PMID: 26494949]|
|||Ludwig Courvoisier (1843-1918). Courvoisier's sign. JAMA. 1968 May 13; [PubMed PMID: 4869570]|
|||Blann A, What is the purpose of liver function tests? Nursing times. 2014 Feb 5-11; [PubMed PMID: 24669469]|
|||Jalan R,Hayes PC, Review article: quantitative tests of liver function. Alimentary pharmacology [PubMed PMID: 7654888]|
|||Bassari R,Koea JB, Jaundice associated pruritis: a review of pathophysiology and treatment. World journal of gastroenterology. 2015 Feb 7; [PubMed PMID: 25663760]|
|||Trotter JF, Liver transplantation around the world. Current opinion in organ transplantation. 2017 Apr; [PubMed PMID: 28151809]|
|||Namas R,Marquardt A, Case Report and Literature Review: Quinacrine-induced Cholestatic Hepatitis in Undifferentiated Connective Tissue Disease. The Journal of rheumatology. 2015 Jul; [PubMed PMID: 26136554]|
|||Shin SJ,Park H,Sung YN,Yoo C,Hwang DW,Park JH,Kim KP,Lee SS,Ryoo BY,Seo DW,Kim SC,Hong SM, Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Cancer research and treatment : official journal of Korean Cancer Association. 2018 Oct; [PubMed PMID: 29268568]|
|||Biggerstaff ME,Short N, Evaluation of specialist referrals at a rural health care clinic. Journal of the American Association of Nurse Practitioners. 2017 Jul; [PubMed PMID: 28695714]|
|||Papatheodoridis G,Thomas HC,Golna C,Bernardi M,Carballo M,Cornberg M,Dalekos G,Degertekin B,Dourakis S,Flisiak R,Goldberg D,Gore C,Goulis I,Hadziyannis S,Kalamitsis G,Kanavos P,Kautz A,Koskinas I,Leite BR,Malliori M,Manolakopoulos S,Matičič M,Papaevangelou V,Pirona A,Prati D,Raptopoulou-Gigi M,Reic T,Robaeys G,Schatz E,Souliotis K,Tountas Y,Wiktor S,Wilson D,Yfantopoulos J,Hatzakis A, Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. Journal of viral hepatitis. 2016 Feb; [PubMed PMID: 26809941]|